Product Pathways - Protein Translation
KEAP1 (H436) Antibody #4617
|4617S||100 µl (10 western blots)||---||In Stock||---|
|4617||carrier free and custom formulation / quantity||email request|
|W||1:1000||Human, Mouse, Rat, Monkey||Endogenous||60-64||Rabbit|
Species cross-reactivity is determined by western blot.
Applications Key: W=Western Blotting, IP=Immunoprecipitation
Specificity / Sensitivity
KEAP1 (H436) Antibody detects endogenous levels of total KEAP1 protein.
Source / Purification
Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding His436 of human KEAP1 protein. Antibodies were purified by protein A and peptide affinity chromatography.
The nuclear factor-like 2 (NRF2) transcriptional activator binds antioxidant response elements (ARE) of target gene promoter regions to regulate expression of oxidative stress response genes. Under basal conditions, the NRF2 inhibitor INrf2 (also called KEAP1) binds and retains NRF2 in the cytoplasm where it can be targeted for ubiquitin-mediated degradation (1). Small amounts of constitutive nuclear NRF2 maintain cellular homeostasis through regulation of basal expression of antioxidant response genes. Following oxidative or electrophilic stress, KEAP1 releases NRF2, thereby allowing the activator to translocate to the nucleus and bind to ARE-containing genes (2). The coordinated action of NRF2 and other transcription factors mediates the response to oxidative stress (3). Altered expression of NRF2 is associated with chronic obstructive pulmonary disease (COPD) (4). NRF2 activity in lung cancer cell lines directly correlates with cell proliferation rates, and inhibition of NRF2 expression by siRNA enhances anti-cancer drug-induced apoptosis (5).
The NRF2 repressor KEAP1 contains an amino terminal BTB/POZ domain and a carboxyl terminal KELCH domain (6,7). The KELCH domain is required for interacting with NRF2 and the BTB/POZ domain functions in binding Cul3 E3 ubiquitin ligase (8-10). Under normal conditions, the complex leads to the cytoplasmic sequestration and ubiquitin-mediated proteasomal degradation of NRF2. Electrophilic modification of KEAP1 leads to disassociation of the NRF2/KEAP1 complex. KEAP1 also targets the down regulation of NF-κB activity by targeting IKKβ degradation (11). Mutation of the corresponding KEAP1 gene is seen in lung cancer cases and can lead to uncontrolled activation of NRF2 (12-14).
- Cullinan, S.B. et al. (2004) Mol Cell Biol 24, 8477-86.
- Nguyen, T. et al. (2005) J Biol Chem 280, 32485-92.
- Jaiswal, A.K. (2004) Free Radic Biol Med 36, 1199-207.
- Suzuki, M. et al. (2008) Am J Respir Cell Mol Biol 39, 673-82.
- Homma, S. et al. (2009) Clin Cancer Res 15, 3423-32.
- Itoh, K. et al. (1999) Genes Dev 13, 76-86.
- Dhakshinamoorthy, S. and Jaiswal, A.K. (2001) Oncogene 20, 3906-17.
- Furukawa, M. and Xiong, Y. (2005) Mol Cell Biol 25, 162-71.
- Zhang, D.D. et al. (2004) Mol Cell Biol 24, 10941-53.
- Kobayashi, A. et al. (2004) Mol Cell Biol 24, 7130-9.
- Lee, D.F. et al. (2009) Mol Cell 36, 131-40.
- Padmanabhan, B. et al. (2006) Mol Cell 21, 689-700.
- Singh, A. et al. (2006) PLoS Med 3, e420.
- Ohta, T. et al. (2008) Cancer Res 68, 1303-9.
- Fan, W. et al. (2010) Autophagy 6, . Applications: Western Blotting.
Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!
This product is intended for research purposes only. The product is not intended to be used for therapeutic or diagnostic purposes in humans or animals.
Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.